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Abstract  
The DHFR system is used for the selection of recombinant CHO cell lines using the inhibitor 
MTX. During clonal selection, endogenous DHFR expression and resistance to MTX allows 
the selection of cells expressing sufficient DHFR to survive. Here we describe a novel vector 
platform for the DHFR system, whereby addition of a synthetic 3’UTR destabilizes DHFR 
expression. We harnessed miRs ability to negatively regulate gene expression by their near-
complementary binding to the 3'UTR region of transcripts. From the literature we identified  
let-7f as a highly abundant, invariant miR in CHO cells. Three 3’UTR targets of the let-7f miR 
were then cloned in the DHFR host 3’UTR to determine the impact on gene expression 
(HMGA2 3’UTR sequence 1, 2 and 3). Using luciferase as a reporter we show down-regulation 
of luciferase activity is mediated by the nature of the 3’UTR and its ability to bind let-7f. We 
then applied the same 3’UTRs downstream of the DHFR gene to show this also results in 
reduced transcript amounts. Finally, we applied this methodology to generate stable DG44-
derived cell pools expressing a model monoclonal antibody, demonstrating this approach can 
be used for the selection of antibody producing cells with low MTX concentrations.  
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Introduction 
Cultured Chinese hamster ovary (CHO) cells are the most commonly utilized industrial 
mammalian cell expression system used for the production of biotherapeutic proteins [1]. 
When using mammalian cell expression systems such as CHO to generate recombinant 
proteins at an industrial scale, the usual approach is to generate and isolate stably expressing 
recombinant cell lines/clones whereby the gene (or genes) of interest are stably incorporated 
into the host genome [2]. The two most commonly utilized selection systems for the generation 
of recombinant CHO cell lines are the glutamine synthetase (GS) and dihydrofolate reductase 
(DHFR) selection systems [3]. GS catalyzes the synthesis of glutamine from glutamic acid, 
ammonia and ATP. In the GS selection system either a host cell where GS is knocked out is 
used and/or endogenous GS is inhibited by L-methionine sulfoximine (MSX) and hence only 
transfectants where exogenous GS is expressed are able to survive selection in glutamine 
free medium containing MSX [3]. The DHFR enzyme catalyzes the synthesis of tetrahydrofolic 
acid from dihydrofolic acid and the inhibitor of DHFR, methotrexate (MTX), is used to select 
for and amplify cells or clones with elevated DHFR expression [4]. The DFHR system is usually 
used in DHFR deficient CHO cell lines (e.g. DG44 or DUXB-11) and via multiple rounds of 
selection with increasing DHFR concentrations (up to 1000 nM) high-producing clones can be 
isolated that contain multiple copies of the DHFR and target recombinant genes [5].  
Although the DHFR system is widely used industrially for the generation of high-
producing recombinant cell lines, the process can be time consuming and labour intensive [6], 
with several rounds of MTX amplification of individual clones often used [7]. Consequently, 
genomic rearrangements can occur upon amplification that leads to instability in the isolated 
clones [5]. In order to improve the process and reduce the timelines for cell line development, 
a number of approaches have been reported. These include the combination of DHFR 
selection with codon optimization of the recombinant gene(s) of interest which when combined 
are reported to result in saturation of gene expression at MTX concentrations as low as 5 nM 
without compromising the recombinant protein yields from the isolated clones and in some 
cases improving product quality [5]. The combination of MTX selection with the use of a 
mammalian replication initiation region (IR) and a matrix attachment region (MAR), (termed 
the IR/MAR-DHFR fusion method) reportedly gave rise to clones with improved antibody 
yields compared to those achieved from either of these methods alone and the clones were 
more stable than those generated from the traditional DHFR/MTX approach [8]. 
Others have approached improving the DHFR selection stringency and system by 
attenuating or reducing DHFR expression. For example, Wu and colleagues used a short 
hairpin RNA targeted to the DHFR gene to generate recombinant IgG expressing CHO clones 
and found that this approach improved IgG expression by more than 100% and genomic 
stability in MTX free culture by 30% [9]. The use of a destabilized-DHFR selection marker 
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linked to an attenuated IRES element has also been shown to be effective in generating high 
yielding recombinant CHO cell lines [10]. The use of a codon de-optimized DHFR selectable 
marker to improve selection stringency in the presence of MTX has also been shown to result 
in enhanced expression of recombinant proteins, showing that reducing translational efficiency 
of DHFR, and hence its expression, can be used to isolate cell lines with improved stringency 
and higher productivities without multiple and time-consuming gene amplification steps [6].  
An alternative method of tuning or attenuating translation, and hence gene expression, 
is via the manipulation of microRNAs (miRNAs or miRs). miRs were first described in C. 
elegans as an antisense RNA regulating the level of LIN-14 protein [11] and are small (20-23 
nucleotides) non-coding RNA molecules that mainly act as negative regulators of gene 
expression by binding to target mRNAs in their 3’UTR inhibiting their translation [12]. Target 
mRNAs can be paired to more than one miR via the 3’UTR region, likewise a single miR can 
in theory target hundreds of unrelated messages and thus it is thought that the influence of 
miRs is wide-ranging. Indeed, the use of miR cell engineering to change the phenotype of 
CHO cells for improved recombinant protein and cell growth characteristics has now been 
reported by a number of groups (e.g. see [13-19]), this approach having the advantage of 
being able to engineer or manipulate multiple pathways simultaneously without placing an 
additional translational burden on the cell that traditional cell engineering approaches impose 
[20]. Here we describe the application of harnessing endogenously expressed CHO miRs to 
mediate DHFR gene expression and hence manipulate selection stringency to develop 
monoclonal antibody (mAb) expressing recombinant CHO cell pools. The approach relies on 
fusing the miRNA target containing 3’UTR sequences to the DHFR gene which is co-located 
with the heavy chain gene in a mAb plasmid expression vector. We show that using this 
approach, endogenous miR expression can be harnessed to enhance the stringency of 
recombinant gene expression selection and demonstrate this leads to generation of 
recombinant CHO cell pools with elevated mAb expression compared to those without the 
miR repression with low concentrations of MTX.  
 
Materials and Methods 
CHO Cell Lines and Cell Culture Protocols 
For the general cloning of genes/isolation of RNA and genomic DNA, and for undertaking 
luciferase expression luminescence experiments, the commercially available CHO-S cell line 
was utilized (ThermoFisher). The DG44 DHFR-/- CHO cell line was obtained from the 
European Collection of Cell Cultures (ECACC, No. 05011002) 
(http://www.hpacultures.org.uk/collections/ecacc.jsp). CHO-S cells were routinely cultured in 
commercially available CD-CHO (ThermoFisher, UK) supplemented with 8 mM L-glutamine, 
in Erlenmeyer flasks (Corning Inc.). For routine sub-culturing, 250 mL flasks containing 50 mL 
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cultures were used.  Cells were sub-cultured every 3 or 4 days with new cultures being seeded 
at 0.2 x 106 viable cells/mL in fresh media. The cells were incubated at 37°C, with shaking at 
100 rpm in a 5% CO2 atmosphere. The concentration and viability of cells was determined on 
a Vi-Cell XR (Beckman Coulter Inc, UK) instrument.  DG44 cells were grown adherently under 
5% CO2 in air conditions at 37oC in 90% Iscove's Modified Dulbecco's Medium (IMDM), 10% 
(v/v) -irradiated, dialyzed foetal calf serum (FCS) (Lonza), supplemented with 2 mM 
glutamine, 0.1 mM hypoxanthine, 0.01 mM thymidine (all ThermoFisher, UK), in flat T-flasks. 
 
Identification of miR 3’UTR Targets using Computational Prediction Software 
The online freeware software packages Targetscan Version 5.2 (http://www.targetscan.org/), 
miRanda (http://www.microrna.org/) and TargetRank (http://genes.mit.edu/targetrank/) were 
used to search against mouse and human databases to identify/predict genes targeted by 
microRNAs of interest. Both software packages utilize genome coordinates for 3’UTRs using 
RefSeq annotations available from UCSC (http://genome.uc.sc.edu/). 
 
Plasmids, Primers and Cloning Strategies  
The commercially available pcDNA4/myc-HIS A plasmid was from ThermoFisher (Catalogue 
no. V863-20). pRLSV40L78 (containing the synthetic 8 let7A target sequence) and pLSVM3’ 
(containing the c-Myc target sequence) were a kind gift from Prof. Bushell, MRC Toxicology 
Unit, University of Leicester [21]. The pPHA79407 and pPHA79408 plasmids are Pfizer Inc 
proprietary constructs containing the genes for the expression of a model monoclonal antibody 
IgG (pHA79407, heavy chain (HC) and DHFR genes; pHA79408 light chain (LC) gene). For 
exogenous expression of miRs, the miR precursors (primiRs) were cloned into the commercial 
pcDNA4/myc-HIS A vector. The human pri-miR coordinates and sequences were obtained 
from the miR database (http://mirbase.org/). All PCR amplified pri-miR hairpins covered at 
least 250 nucleotide flanking sequences on either side of the pri-miR and were amplified using 
the forward and reverse primers detailed in Supplementary Table 1 (restriction sites for cloning 
in each primer underlined). For the cloning of the human HMGA2 3’UTR fragments into the 
pRL vector, the sequence was retrieved from Ensembl (http://www.ensembl.org/index.html/). 
All primer sequences utilized for amplifying target 3’UTRs and cloning into the pRL vector are 
detailed in Supplementary Table 2. Primers for introducing the EcoRV and KpnI restriction 
sites into the Pfizer pPHA79407 plasmid were designed using Stratagene’s web-based 
QuikChange Primer Design Program (http://www.stratagene.com/qcprimerdesign/). The 
3’UTRs were cloned into the resulting plasmid termed pPHA79407 E/K as EcoRV/KpnI 
fragments using the primer sequences described in Supplementary Table 3. Primers used for 
qRT-PCR mRNA analyses are described in Supplementary Table 4. Site-directed 
mutagenesis was undertaken using the QuikChange Lightning Site-Directed Mutagenesis Kit 
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(Stratagene). Genomic DNA was isolated using the commercially available FlexiGene DNA 
kit (Qiagen). 
 
RNA Isolation and qRT-PCR Assays for the Determination of Relative mRNA Amounts 
Total RNA was isolated from cell pellets using an RNeasy Mini Kit (Qiagen). qRT-PCR was 
carried out in sealed low 96-well white plates (BioRad multiplate PCR plates) using the 
QuantiFast SYBR Green RT-PCR kit (Qiagen) and the gene specific primers designed (see 
Supplementary Table 4) as previously described [22]. PCR reactions were run on a BioRad 
DNA engine with CHROMO4 continuous fluorescence detector and analyzed using Opticon 
Monitor 3.1 software and the following program (50ºC 10 min, 95ºC 5 min, 40 cycles of 95ºC 
10 sec, 58ºC 30 sec, plate read and followed by a melting curve 58ºC to 95ºC, read every 
0.5ºC, hold 1 sec).  
 
Transfection of Plasmid DNA into CHO Cells 
Transient transfections were carried out using Lipofectamine LTX (ThermoFisher). Transient 
transfection experiments were undertaken in 6-well plates and at the time of transfection 0.8 x 
106 cells/well were mixed with 2 g of the relevant plasmid. CHO-S suspension cells were 
seeded immediately prior to transfection whilst DG44 adherent cells were seeded 24 h prior to 
transfection. Stable transfection of DG44 cells was undertaken using electroporation. Briefly, 
80 µg each of both light and heavy chain plasmids, linearized using the restriction enzyme 
NotI, were used to transfect 1.25 x 107 viable cells in 0.4 cm pulse cuvettes (BioRad) by 
selecting the exponential decay programme on a Biorad Gene Pulser Xcell system (300 V, 950 
µF capacitance and infinite resistance). Following electroporation, the cells were gently 
transferred to flat T75 flasks (final volume 20 mL) and placed in a static 5% CO2 incubator at 
37.0°C.  
 
Selection and Amplification of DHFR Positive Cell Pools 
Two days post-transfection, cells expressing DHFR were selected for by removing the HT 
supplement  and growing in 90% IMDM, 10 % θ-irradiated dialyzed FBS, and grown in T-75 
flasks containing 5 or 10 nM MTX. Cells were then returned to the incubator for an extra 7 to 
14 days. The cells were then left for 2 weeks for colonies to grow and then amplification 
continued up to 6 weeks by sub-cultuirng every 3 or 4 days in the presence of the appropriate 
amount of MTX (5 or 10 nM) at which point cell pools were cryopreserved. 
 
ELISA for the Determination of IgG Amounts in Cell Culture Supernatants 
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The concentration of assembled IgG in supernatant of cell pools was assessed by ELISA as 
previously described [23].  
 
Reporter Gene Analysis 
For determining Renilla luciferase activity we used the commercially available Renilla-Glo 
Luciferase Assay system (Promega). For the measurement of Gaussia luciferase activity in 
the cell culture supernatant we used the commercially available Gaussia Luciferase Assay kit 
(New England Biolabs, NEB). For both methods, the luminescence was measured after a 10 
min equilibration period.  
 
Statistical Testing 
ANOVA analysis was used for statistical testing followed by post hoc Tukey’s test analysis. 
 
Results 
Selection of endogenous miRs and target 3’UTRs to mediate repression of DHFR expression 
Our approach to mediate repression of DHFR expression was to utilize endogenous CHO 
miRs that are highly expressed with little variation throughout culture, that would target specific 
3’UTRs and could be introduced onto the DHFR mRNA. This would circumvent the need to 
engineer the miR in the cell to achieve repression of DHFR expression that might perturb cell 
physiology. Further, it was necessary to consider that the introduction of the exogenous DHFR 
with a 3’UTR targeted by a specific miR may titrate down endogenous levels of that specific 
miR. Therefore, for our application it was desirable to utilize miRs that are naturally abundant 
within the host cell.  
We initially scanned the literature to identify miRs with low variability across culture 
conditions (i.e. the miR concentration was independent of the CHO cell subtype, the medium, 
and was maintained at high concentrations relative to other miRs throughout culture). The 
initial miRs were selected based upon the data published by Johnson et al who reported on 
the prevalence of miRs in CHO cells using high-throughput sequencing in six cDNA libraries 
generated from four different cell lines [18]. The authors of this study identified 350 miR/miR* 
sequences by homology to other species and established that there was a range of 
expressions of these miRs. The read counts plotted in Figure 1A, on a log10 scale, show the 
25 miRs (from the 350) exhibiting the lowest variability in abundance compared to the other 
miRs identified in the study across the six libraries investigated. The nomenclature used in 
Figure 1A corresponds to the species that showed the best match in the miRbase reference 
sequence to the CHO small RNA sequence obtained by deep sequencing. Variability was 
assessed by calculating the ratio of the mean abundance of the miRs to the standard deviation 
(SD). Interestingly, members of the conserved let-7 family were highly-represented in terms 
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of being very abundant with low variability across the libraries (Figure 1A). Let-7f was the most 
abundant miR ranging from 650,000 to 1.4 million copies per cell (Figure 1A) [18]. As this miR 
was naturally abundant, we assumed that its expression would not need to be artificially 
modulated to repress let-7f specific 3’UTR target mRNAs. We therefore selected let-7f as the 
miR for which we would look for suitable 3’UTR targets that might be utilized when placed in 
the 3’UTR of appropriate transcripts (in this case DHFR) to repress their expression.  
 In order to identify 3’UTRs that are a target of the let-7f miR we used in silico prediction 
software. The limitation of using in silico prediction methods to identify miR 3’UTR targets for 
a specific miR is that miR:mRNA pairing programs often show very little overlap or agreement 
in their predictions [24-25]. However, such approaches are useful in identifying potential 
targets for further evaluation and hence we used the freeware software programmes 
TargetScan (www.targetscan.org), miRanda (www.microrna.sanger.ac.k/targets) and 
TargetRank (http://genes.mit.edu/targetrank/) for initial target prediction. We ran a search for 
human let-7f mRNA targets using TargetScan version 5.2 and compared the top 10 hits with 
those retrieved from miRanda and TargetRank (Table 1). From the potential targets identified, 
we chose the 3’UTR of HMGA2 as a potential match for let-7f binding to place in the 3’UTR of 
target transcripts such that their expression would be repressed by let-7f (Table 1).  
 The human HMGA2 3’UTR is long at 2996 bp and harbors five predicted conserved, 
and one predicted non-conserved, binding sites for let-7f (Figure 1B). The pPHA79407 
plasmid which carries the DHFR marker is 7915 bp and the DHFR native 3’UTR is 
approximately 1000 bp. Replacing the latter with the full HMGA2 3’UTR would have resulted 
in a vector over 10 kb and could have potentially reduced the overall transfection efficiency of 
the plasmid. We therefore opted to clone partial HMGA2 3’UTR sequences onto the 3’UTR of 
DHFR. We selected three regions (as highlighted in Figure 1B), each one containing a different 
seed region, the nucleotides 2-7 or 2-8 of the miR 5’ end that are responsible for initiating 
mRNA binding. As the nature of the seed impacts on the degree of regulation, an 8mer seed 
being the strongest and 7merA1 the weakest [25], we hypothesized that region 1 (1 x 8mer), 
2 (2 x 7mer-m8, 1x7mer-A1) and 3 (1x7mer-A1) might give differential translational repression. 
A complete repression of DHFR expression would be unsuitable for our purposes and this 
was thus a further basis for utilizing partial HMAGA2 sequences rather than the full length 
3’UTR. The full length 3’UTR encompasses all the identified potential regulation sites and 
hence might result in very high repression of target 3’UTR constructs compared to the partial 
sequences. 
 In parallel to using the HMGA2 target sequences identified via the bioinformatics 
approach described above, we obtained two constructs containing 3’UTR miR targets. The 
first construct contained the c-myc 3’UTR and the second a synthetic cassette 8let-7A which 
are targeted by miR34c and let-7a, respectively. Previous work has already demonstrated that 
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the presence of these target sequences results in the repression of renilla luciferase when 
placed downstream of the open reading frame and that the repression was relieved in the 
presence of the antisense oligonucleotide (anti-mIR) for the appropriate miR (miR34c or let-
7a [21]). These targets were therefore validated and were a positive control for the luciferase 
assay. 
 
Functional validation of repressed gene expression in CHO cell lines by the presence of 
3’UTRs targeted by specific miRs  
Having identified 3’UTRs that should be targeted by endogenous high abundant miRs in CHO 
cells, it was necessary to validate that the presence of the 3’UTRs on specific recombinant 
mRNAs resulted in repression of expression at the protein level. To achieve this, we fused the 
target 3’UTRs onto the open reading frames of the reporter Renilla luciferase in transient 
expression studies. Renilla luciferase is retained in the cytoplasm of the cell as the DHFR 
protein would be. When the wild-type 3’UTR of the Renilla luciferase was replaced with any 
of the HGMA2 regions, the c-myc 3’UTR or synthetic let-7a the luciferase expression was 
dramatically repressed (Figure 2A). When constructs for the expression of exogenous pri-
miRs to elevate the amount of miRs present were co-transfected with the luciferase 
constructs, no additional repression was observed (Figure 2A). This suggests that 
endogenous miR amounts are not limiting repression and hence repression could not be 
further enhanced by over-expressing the specific miRs. The repression of Renilla luciferase 
expression indicated that the HGMA2 region 1 and 2 3’UTRs gave rise to the largest 
repression in reporter gene expression compared to the control (approximately 90%) whilst 
the HGMA2 region 3 3’UTR harboring construct reduced the expression by approximately 
75% compared to the control (Figure 2A). 
 To determine if the same 3’UTRs could also repress DHFR expression we sub-cloned 
all the 3’UTRs downstream of the DHFR marker in the pPH79407 E/K heavy chain expressing 
vector. To this end, the 3’UTRs (HMGA2 sub-regions 1, 2 and 3 as well as the c-myc and let-
7a miR target cassettes) were amplified as EcoRV/KpnI fragments using pGL as a template 
and the primers described in Supplementary Table 3. Figure 2B (left-hand bar for each set) 
shows that for all five 3’UTR variants (HMGA2 1, 2, 3, let7a cassette and c-myc cassette), 
following transient transfection in CHO-S cells the amount of DHFR mRNA was reduced when 
compared to the control construct. The endogenous DHFR mRNA levels were negligible in 
comparison to that observed in the pPHA79407 E/K control 3’UTR (Figure 2B, Null). The drop 
in the relative amounts of the DHFR mRNA implies that 3’UTR-mediated regulation of DHFR 
leads to mRNA degradation, even though miR mediated repression can result in either 
inhibition of translation (and no change to mRNA levels) or degradation. We could not however 
confirm a reduction at the protein level (not shown) as we could not detect DHFR protein by 
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western blot analysis even in the control pPHA79407 E/K transfection experiment (although 
the western blot assay was shown to be working using a positive control for DHFR, data not 
shown). Collectively these data suggest that the 3’UTRs identified were able to lead to 
repression of gene expression and were thus suitable for use in repressing DHFR expression 
for the purpose of modulating selection stringy during stable integration of recombinant genes. 
 
Application of the miR target-containing 3’UTRs in the DHFR system for recombinant IgG 
production 
Having established that the selected 3’UTRs could result in repression of transgene 
expression, we then applied this to DHFR expression coupled to IgG production. pPH79407 
E/K and its derivatives bearing HMGA2 1, 2, 3, let7a cassette and c-myc cassette were 
therefore co-transfected with the light chain vector (pPHA79408) into the DG44 (DHFR-/-) host 
and initially transient expression of IgG was analyzed by ELISA (Figure 3A). The ELISA data 
showed that 24 hour post-transfection, the amount of IgG secreted from the cells transfected 
with the miR target containing 3’UTR vectors was lower than that of the controls (Figure 3B). 
However, this trend was reversed at 48 h post-transfection (Table 2), suggesting that post-
transcriptional repression of DHFR does not in the long term affect the overall expression of 
the heavy chain and ultimately IgG production in a transient system. 
Although there was a small benefit in transient expression of IgG using the miR 
targeted 3’UTRs, these constructs were designed to facilitate stable cell line construction via 
the repression of DHFR expression. In this way, during stable cell line construction the system 
would select for those stable integrants that were expressing the highest amounts of DHFR, 
presumably due to the cassette being integrated into sites with high transcriptional activity. 
We therefore used the 3’UTR repressed DHFR system to construct stable pools expressing 
the target IgG. To generate the stable pools we transfected the different constructs into the 
DG44-deficient host cell line and then selected for DHFR positive cells using 5 or 10 nM MTX. 
All measurements were made in triplicate. Figure 3B and Table 2 show the amount of IgG1 
from each of the pools that resulted using the different 3’UTR constructs as determined using 
ELISA. In our hands, cells originally transfected with pPHA79407 bearing HMGA2 3 3’UTR 
died when exposed to MTX concentration greater than 5 nM MTX. Polyclonal populations 
originally transfected with pPHA79407 E/K bearing HMGA2 1 3’UTR or the 8-let-7a cassette, 
exhibited higher IgG levels following gene amplification at both 5 nM and 10 nM MTX 
compared to the control. However, the change in absorbance in the ELISA reflective of IgG 
production between the no MTX control and the MTX containing pools was greatest in HMGA2 
1 pools at 10 nM MTX. This result was consistent with our earlier observation that the HMGA2 
1 3’UTR led to reduced gene expression (see luciferase in Figure 2A and DHFR in Figure 2B). 
The data therefore collectively suggest that the described approach which is a novel way to 
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elicit repression of gene expression of DHFR can be  associated with MTX selection, at low 
concentration, to screen mAb producing polyclonal pools prior to cloning out cells. 
 
Discussion 
The DHFR system and use of the MTX inhibitor is widely used for the generation of 
recombinant cell lines when using DHFR deficient CHO host cell lines [8, 26-28]. The 
traditional approach to generating recombinant pools of cells and clonal populations using this 
approach is labor intensive and as described in the introduction, there have been a number of 
reports to modify the approach to reduce the time and labor required to generate cell lines. 
Further, whilst this approach can be used to amplify recombinant gene copy number, the MTX 
inhibitor of the DHFR enzyme is cytotoxic and mutagenic and its use can lead to unwanted 
mis-translation and mis-incorporation of amino acids into recombinant proteins [29]. As such, 
being able to reduce the concentration of MTX required to obtain appropriate cell lines would 
be advantageous.  
 Here we have identified from the literature highly abundant miRs in CHO cells and 
used this information to select a panel of 3’UTRs targeted by these endogenous and highly 
abundant miRs for repression of the DHFR marker. The majority of studies into miRs in CHO 
to date have focused upon profiling or manipulation of miR amounts (e.g. [30-31]), but here 
we focused upon utilizing endogenous amounts of highly expressed and conserved miRs. 
Selecting and exploiting the endogenous miR profile of the cell means that miR mediated 
repression would in theory not require the manipulation of the miR itself which could result in 
unwanted side-effects in terms of changing the gene expression of the CHO host. With this in 
mind, let-7f was selected as the endogenous miR for which target 3’-UTR s were identified to 
place on the DHFR gene as previous reports show this miR to be highly expressed across 
hosts/clones [18]. We would therefore not expect let-7f expression to be lost due to clonal 
stability as manipulation of let-7f expression was not required. This should help circumvent, 
as far as possible, issues around stability and lost expression. The high expression of let-7f 
means that even with the DHFR transcript acting as a sponge for this miR, we assumed it 
would not significantly deplete this miR and thus impact on other CHO cell processes reliant 
on let-7f expression.  
Using the approach of placing let-7f target UTRs on the DHFR , the selected 3’UTRS 
were able to repress reporter gene expression as shown using luciferase as a model system. 
Although we do not have direct evidence that the repression is due to the miRs targeting the 
3’UTRs, the reduction in luciferase expression and mRNA in the presence of the specific 
3’UTRs suggests that this is likely to be the case. We could not use sponge vectors that ‘mop-
up’ miRs [32] to show that this reduced the repression as the chosen miRs are among the 
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most highly abundant present and hence reducing these significantly would be exceedingly 
difficult.  
 We then applied our 3’UTRs in the DG44 DHFR null host CHO cell line and used a 
heavy chain vector containing the DHFR selection gene with various 3’UTRs to rescue the 
deficiency in folate metabolism in the presence of MTX. In this system, resistance to the folic 
acid analogue, methotrexate, require stable integration of the DHFR marker in highly 
transcribed sites and co-selection for the enhanced expression of the heavy chain of the model 
IgG1 used in this study. We also wanted to minimize the concentration of MTX utilized to 
generate antibody expressing cell pools and thus the selection procedure used 5-10 nM MTX 
to limit detrimental effects on cellular fitness and potential mutations. The selected repressed 
3’UTRs and subsequent ELISA determination of mAb amounts observed early in the cell line 
development phase were compared to a standard 3’UTR used on the DHFR selection marker 
at Pfizer. In each case, higher ELISA readings were obtained for the selected 3’UTRs 
compared to the control.  
 The data shown in this study collectively demonstrates the feasibility of using 3’UTR 
manipulation of the DHFR gene to improve the time and product yield from CHO DHFR 
deficient pools using low concentrations of MTX for selection. Further, our data across the 
luciferase and antibody studies suggests that using 3’UTRs targeted by highly endogenous 
miRs in the CHO cell can be used to rapidly generate pools expressing a gene of interest. In 
particular, our data suggests that the 3’UTR/miR pair let-7f and HMGA2-1 can be used as a 
tool to repress the DHFR selection system in DG44 (DHFR-/-) cells and enhance the 
productivity observed in surviving cells. Interestingly, the 3’UTR of the human DHFR mRNA 
has a natural polymorphism for the miR-24 binding site that results in MTX resistance [33]. It 
may therefore be possible to further manipulate the 3’UTR of the DHFR mRNA used for 
selection purposes in CHO cell line construction to either enhance or reduce the repression 
of DHFR expression in tandem with miR-24 or other miR binding sites. Use of such a miR-
mediated DHFR repression approach also has the advantage over other selection methods 
that use drug inhibitor approaches alone in that the data here suggests lower drug 
concentrations can be used to obtain the same or better results and that the repression is 
independent of the selection system. This enables the application of this technology to other 
selection markers or approaches and for the user to maintain stable cell pools using lower 
drug concentrations, giving the methodology versatility in that it could be applied to a wide 
range of recombinant protein expression systems. 
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Figure Legends 
Figure1. A. The top 25 miR species (from the 350) that exhibited low variability in abundance 
compared to other miRs across a panel of six CHO miR libraries previously reported by 
Johnson et al [18]. The results are plotted on a log10 scale. Variability was assessed by 
calculating the ratio of the mean abundance of the miRs to the standard deviation 
(SD), n=6 B. let-7f binding sites onto the HMGA2 3’UTR, according to TargetScan (Version 
5.2): sites marked in light shade are conserved across species while the site marked in black 
shade is poorly conserved.  
 
Figure 2. A. Renilla luciferase activity in CHO-S cells, 24 h post transfection with plasmid 
constructs, using lipofection. AOVA analysis shows an overall P value of 1.85 E-10. All data 
are significantly different to pRSLSV40 (Control) as determined by Tukey’s Honestly 
Significant Difference criterion. None of the pairwise comparison (endogenous versus 
exogenous) show significant statistical difference. B. The DHFR mRNA levels were quantified 
by qRT-PCR for all 3’UTR variants in transiently transfected CHO-S cells. Bars represent 
standard deviation, samples were analyzed in triplicates. 
 
Figure 3. A. The amount of actively bound lambda chain was measured by ELISA in 
transiently transfected DG44 (DHFR-/-) cell ines at 24 h and 48 h post transfection. B. For all 
variants, the level of actively bound lambda chain was measured by ELISA in DG44 (DHFR-
/-) stable lineage (polyclonals). The polyclonal pools were passaged three-four times under 
selection pressure. Bars represent standard deviation, samples were analyzed in triplicates. 
ANOVA analysis for dataset with 5 nM MTX shows an overall P value of 7.85 E-15 while 
ANOVA analysis for dataset with 10 nM MTX shows an overall P value of 0.000361. This can 
be explained by a greater variability within the 10 nM MTX dataset. For HMGA2 REG1 there 
was a significant difference between control and 10 nM MTX treatment (p value of 0.0012) 
while no significant difference was observed at 5 nM MTX (p value of 1). 
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Table 1. hsa-let-7f mRNA target predictions as inferred by TargetScan (Version 5.2), 
TargetRank and miRanda.  
 
Target 
gene 
prediction: 
TargetScan 
Version 5.2 
Gene Name Target 
gene 
prediction: 
TargetRank 
Target 
gene  
prediction: 
miRanda 
HMGA2 High mobility group AT-hook 2 C14orf28 HMGA2 
C14orf28 chromosome 14 open reading frame 28 HMGA2 IGF2BP1 
LIN28B lin-28 homolog B (C.elegans) TRIM71 LIN28B 
FIGNL2 fidgetin-like 2 DNA2 CLCN5 
TRIM71 Tripartite motif-containing 71 SMARCAD1 C14orf28 
IGF2BP1 Insulin-like growth factor2 mRNA binding 
protein 1 
ESR2 ARID3B 
PUNC Putative neuronal cell adhesion molecule EDN1 IGFIR 
ARID3B AT rich interactive domain 3B (BRIGHT-
like) 
FIGN LOC401720 
FIGN fidgetin FIGNL2 FIGN 
THRSP Thyroid hormone responsive (SPOT14 
homolog, rat) 
CTPS2 PUNC 
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Table 2. Fold-increase in antibody production after treatment with either 5 nM or 10 nM MTX, 
compared to non-treated samples (n = 3). 
 
 
 
Fold increase 
(ELISA) 
 
5 nM MTX 10 nM MTX 
CON 1.4 1.5 
HMGA2- REG1 1.0 14.6 
HMGA2- REG2 0.8 3.4 
HMGA2- REG3 1.3 
 
c-myc 0.7 0.6 
8-let-7A 1.4 2.0 
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Figure 1. 
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Figure 2. 
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Figure 3 
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